Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately. (See "Society guideline links: Cannabis use disorder and withdrawal".)
International
●Multinational Association of Supportive Care in Cancer (MASCC): Guideline on cannabis for cancer-related pain and risk of harms and adverse events (2023)
●MASCC: Guideline on cannabis for psychological symptoms including insomnia, anxiety, and depression (2023)
●MASCC: Expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer (2022)
●The Cannabinoids International Experts Panel: Epilepsy and cannabidiol – A guide to treatment (2020)
Canada
●American College of Chest Physicians (CHEST) and Canadian Thoracic Society (CTS): Clinical practice guidelines for cannabis and cannabinoid-based medicines in the management of chronic pain and co-occurring conditions (2023)
●British Columbia Guidelines and Protocols and Advisory Committee (GPAC): Managing patients with pain in primary care guideline – Part 2 (2022)
●Canadian Family Physician (CFP): PEER simplified chronic pain guideline for management of chronic low back, osteoarthritic, and neuropathic pain in primary care (2022)
●Society of Obstetricians and Gynaecologists of Canada (SOGC): Guideline No. 425a – Cannabis use throughout women's lifespans. Part 1: Fertility, contraception, menopause, and pelvic pain (2022)
●Canadian Rheumatology Association (CRA): Position statement – A pragmatic approach for medical cannabis and patients with rheumatic diseases (2019)
●CFP: Simplified guideline for prescribing medical cannabinoids in primary care (2018)
United States
●National Center for Complementary and Integrative Health (NCCIH): Cannabis (marijuana) and cannabinoids – What you need to know
●American Academy of Neurology (AAN): Guideline on complementary and alternative medicine in multiple sclerosis (2014, reaffirmed 2023)
●American College of Chest Physicians (CHEST) and Canadian Thoracic Society (CTS): Clinical practice guidelines for cannabis and cannabinoid-based medicines in the management of chronic pain and co-occurring conditions (2023)
●Society of Gynecologic Oncology (SGO): Clinical practice statement on use of cannabinoids in cancer patients (2020)
●American Society of Clinical Oncology (ASCO): Clinical practice guideline for management of chronic pain in survivors of adult cancers (2016)
●American Glaucoma Society (AGS): Position statement on marijuana and the treatment of glaucoma (2009)
United Kingdom
●The BMJ: Medical cannabis or cannabinoids for chronic pain – A clinical practice guideline (2021)
●National Institute for Health and Care Excellence (NICE): Guideline on cannabis-based medicinal products (2019, updated 2021)
Australia–New Zealand
●Choosing Wisely Australia: Use a 'universal precautions' approach for all psychoactive medications that have known potential or liability for abuse including opioids, benzodiazepines, antipsychotic medications, gabapentinoids, cannabinoids and psychostimulants.
●Royal Australian & New Zealand College of Psychiatrists (RANZCP): Therapeutic use of medicinal cannabis products (2021)
●Australian Government Department of Health: Guidance for the use of medicinal cannabis in Australia – Overview, Version 1 (2017)
●Palliative Care Australia (PCA): Position statement on use of medicinal cannabis products in palliative care (2017)
